$GILD Lowered expectations could help when company reports first-quarter results

0
378

Gilead earnings: Lowered expectations could help when company reports first-quarter results

Gilead Sciences Inc. will be grappling with severely lowered expectations when the company reports first-quarter earnings, scheduled for Tuesday after the bell. But that might actually be a good thing for the Foster City, Calif.-based biopharmaceutical company GILD, +0.53% Wall Street analysts say. The company issued lowered 2017 sales guidance earlier this year after disappointing fourth-quarter sales, including big sales declines among the company’s hepatitis C drugs, Harvoni and Sovaldi. They cure the infectious disease and cost about $80,000 for a course of treatment. That guidance came in lower than Wall Street analysts expected, and some believe that could lift the company to a slight beat

LEAVE A REPLY

Please enter your comment!
Please enter your name here